Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Mylan Pharmaceuticals, a Viatris unit, asked the court Thursday to rule that its generic product would not infringe Novo Nordisk's patent for a method of administering single-dose Wegovy pens for weight loss. Should you buy NVIDIA right now? Before you decide, consider this: an AI-powered list of stock picks is outperforming the market by 120%, and it updates at the start of every month.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.